TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05458219: A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 470 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT05458219 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05458219 Rescue Dossier →